Neoceuticals News
Issue 1 – July 2022
Successful renewal of the NeoMag licence
On 27th of April, MHRA granted Neoceuticals’ application for the renewal of the license of our bestselling product, Neomag 4 mmol chewable tablets.
Headline News
The licence of our Neomag 4 mmol chewable tablets was first granted in January 2017 and the licence renewal application was submitted in September 2021. MHRA granted the renewal in April 2022. This means that Neoceuticals will remain as MAH for Neomag indefinitely. This is an important milestone in Neoceuticals’ history.
Neomag 4 mmol chewable tablets is a prescription only medicine containing magnesium glycerophosphate as an active ingredient. The tablets are sugar free with a pleasant taste. They are used for the treatment of patients with chronic magnesium loss or hypomagnesaemia (abnormally low levels of magnesium in the blood) which frequently occurs with certain chemotherapy regimens, organ transplants and alcoholism.
This product is distributed by Alliance Healthcare in UK to hospitals and pharmacies. For more information, please visit: www.neo-ceuticals.co.uk/Product
“Successful renewal of Neomag licence is an important milestone in Neoceuticals’ history”
Other News
New looks of Neoceuticals’ website – Neoceuticals’ website has been redesigned and updated. I will go live on 1 July 2022. Please visit: www.neo-ceuticals.co.uk
Change of the owners – Neoceuticals has been accquired by Guangxi Minglei Weisheng Pharmaceutical Co.Ltd in Spetember. A new management team is in place to take over the operation of the company. Contact us
Neoceuticals Ltd
The Innovation Centre
Innovation Way
Heslington
York YO10 5DG
Tel: 01904 567608
E-mail: infor@neo-ceuticals.co.uk